TEFAF SUPPORTS CANCER RESEARCH
Cancer is the most common cause of death in the world today. One out of three people is diagnosed with cancer at some point in their lives, and fifty percent of those diagnosed will die of the disease, despite such treatments as radiation therapy, chemotherapy and surgery. In the next ten years, the number of diagnoses of cancer will greatly increase, but the tide can be reversed by scientific cooperation on an international scale. Funding is crucial in ensuring that researchers can continue their work to beat cancer, and since 2005 TEFAF has supported research and international collaboration by means of a special Chair of Oncology at the research institute GROW, the School for Oncology and Developmental Biology at the Maastricht University Medical Centre.
A strong impulse to achieve international cooperations
Dr. Christopher Wild
has been appointed as Visiting Professor and TEFAF Chair of Oncology for 2018.
Since 2009 he is the Director of the International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization.
Dr. Wild has published many important studies on the role of environmental and dietary factors as a cause of cancer. The main research interest of Dr. Wild is to understand the interplay between environmental and genetic risk factors in the causation of human cancer. He therefore proposed the concept of the “exposome” and studies its interaction with the genome. The exposome concept refers to the totality of environmental exposures from preconception onwards, and is a novel approach to studying the role of gene-environment interactions in the development of human disease.
Dr. Wild obtained his PhD in 1984 from the University of Manchester, UK, and was awarded an IARC postdoctoral fellowship and subsequently a UK Royal Society European Exchange Fellowship at the Netherlands Cancer Institute, Amsterdam. In 1987, he rejoined IARC as a staff scientist and later became Chief of the Unit of Environmental Carcinogenesis. In 1996, he was appointed to the Chair of Molecular Epidemiology at the University of Leeds; he headed the Centre for Epidemiology and Biostatistics and became Director of the Leeds Institute of Genetics, Health and Therapeutics in December 2005.
He has several awards to his name, such as the Science Award for Outstanding Scientific Article 2003 from the Consultative Group on International Agricultural Research (CGIAR), the UK Molecular Epidemiology Group 10th Anniversary Medal in 2006, and is Fellow of the European Academy of Cancer Sciences, European Cancer Organisation (ECCO), Brussels, Belgium from 2010 onwards.
THE FUTURE OF CANCER MANAGEMENT
THE TEFAF ONCOLOGY CHAIR SUMMIT AT MAASTRICHT PATHOLOGY 2018 MEETING
In the next ten years, the number of cancer diagnoses will increase. At the same time, novel cancer diagnostics and therapeutics will be developed.The coming decades will show an increased understanding of cancer biology and a plethora of innovations in cancer prevention and management. In order to translate these developments efficiently to the cancer patient, scientific collaboration at an international scale is warranted.
Since 2006, the European Fine Art Fair (TEFAF) is supporting international collaboration in cancer research by funding a special Chair of Oncology for visiting professors at GROW, the School for Oncology and Developmental Biology at Maastricht UMC+.
In a special symposium at MECC Maastricht on Friday June 22nd, 2018
, we celebrate 10 years of TEFAF Oncology Chairs. The latest accomplishments and future developments in cancer epidemiology, prevention, biology, diagnostics and therapy will be discussed by the TEFAF Oncology Chairs and other eminent scientists.
Should you be interested in attending this TEFAF Summit please visit www.path.org.uk
for more programme details and registration.
Further funding is necessary in the battle against cancer
The Cancer Research Fund Limburg collects money for cancer research at the Maastricht University Medical Centre. Research into preventing and curing cancer is much needed, but it is only through international collaboration between researchers that the battle against cancer can be won. The aim of the Cancer research fund is to decrease the incidence of cancer and increase the number of people who recover from this disease by raising funds, specifically The Cancer Research Fund
founded by Health Foundation Limburg (HFL), Maastricht University Medical Centre + (Maastricht UMC +)
and the Dutch Wilhelmina Foundation / Cancer Research Foundation (KWF)
. The foundation has a passionate ambassador in internationally renowned violinist Andre Rieu
, who was born in Maastricht.
For further information visit www.kankeronderzoekfondslimburg.nl
or you can donate directly to NL06INGB0005043912.